Non-winterized, standardized marine source oil products and methods of making thereof

A liquid medicament/supplement composition consisting of:

• (a) a non-winterized marine source oil from at least one of fish, krill, squid, or any combination thereof;
• (b) a pharmaceutically acceptable form of vitamin D3 or a derivative thereof admixed in the non-winterized marine source oil;
• (c) a pharmaceutically acceptable form of vitamin A or a derivative thereof admixed in the non-winterized marine source oil;
• (d) optionally a pharmaceutically acceptable form of CoenzymeQ10 or a derivative thereof admixed in the non-winterized marine source oil;
• (e) a polyphenol rich vegetable oil at a concentration of less than 25 wt % of total liquid weight of the composition;
• (f) concentrated eicosapentaenoic acid or ethyl ester, glyceride ester or salt of the acid, concentrated docosahexaenoic acid or ethyl ester, glyceride ester or salt of the acid, or mixtures thereof at a concentration of less than 20 wt % of total liquid weight of the composition;
• and
• (g) a pharmaceutically acceptable form of melatonin or a derivative thereof admixed in the non-winterized marine source oil, wherein:
• the liquid medicament/supplement composition having a totox of less than 5, and
• the liquid medicament/supplement composition has an overall eicosapentaenoic acid to docosahexaenoic ratio (DHA:EPA) calculated as weight % of the free acids ranging from 2:1 to 1:2 at concentration ranging from 15 to 35 wt % of total liquid weight of the composition.

A container comprising:

• a chamber containing a liquid medicament/supplement composition, and
• a cap removably, threadly engaged to a top portion of the chamber to seal the chamber, the cap having an inverted nipple such that the internal nipple protrudes into the chamber when the cap threadly engages the top portion of the chamber thereby reducing and/or limiting air within the chamber, wherein:
• the liquid medicament/supplement composition contained in the chamber consists of:
• (a) a non-winterized marine source oil from at least one of fish, krill, squid, or any combination thereof,
• (b) a pharmaceutically acceptable form of vitamin D3 or a derivative thereof admixed in the non-winterized marine source oil,
• (c) a pharmaceutically acceptable form of vitamin A or a derivative thereof admixed in the non-winterized marine source oil,
• (d) optionally a pharmaceutically acceptable form of CoenzymeQ10 or a derivative thereof admixed in the non-winterized marine source oil,
• (e) a polyphenol rich vegetable oil at a concentration of less than 25 wt % of total liquid weight of the composition;
• (f) concentrated eicosapentaenoic acid, concentrated docosahexaenoic acid, or ethyl ester, glyceride ester or salt of the acid or mixtures thereof, and
• (g) a pharmaceutically acceptable form of melatonin or a derivative thereof admixed in the non-winterized marine source oil, wherein:
• the liquid medicament/supplement composition having a totox of less than 5, and
• the liquid medicament/supplement composition has an overall eicosapentaenoic acid to docosahexaenoic acid ratio (DHA:EPA) ranging from 2:1 to 1:2 in a concentration ranging from 15 to 35 wt % of total liquid weight calculated as weight % of the corresponding free acids.

A method of producing a liquid medicament/supplement composition comprising:

• providing a non-winterized marine source oil having a totox of less than 5;
• admixing a pharmaceutically acceptable form of vitamin D3 or a derivative thereof in the non-winterized marine source oil;
• admixing a pharmaceutically acceptable form of vitamin A or a derivative thereof in the non-winterized marine source oil;
• optionally admixing a pharmaceutically acceptable form of CoenzymeQ10 or a derivative thereof salt thereof in the non-winterized marine source oil;
• adjusting eicosapentaenoic acid ratio in the non-winterized marine source oil, docosahexaenoic acid in the non-winterized marine source oil, or a combination thereof by admixing concentrated eicosapentaenoic acid, concentrated docosahexaenoic acid, or a combination thereof with the non-winterized marine source oil;
• and
• adjusting EPA and DHA concentration by admixing a polyphenol rich vegetable oil with the non-winterized marine source oil, the admixed polyphenol rich vegetable oil being present at a concentration of less than 25 wt % of total liquid weight of the liquid medicament/supplement;
• optionally admixing melatonin or a salt thereof in the non-winterized marine source oil thereby producing the liquid medicament/supplement composition, wherein:
• the liquid medicament/supplement composition has a totox of less than 5, and
• the liquid medicament/supplement composition has liquid medicament/supplement composition has an overall eicosapentaenoic acid to docosahexaenoic (acid) ratio (DHA:EPA) ranging from 2:1 to 1:2 at a concentration ranging from 15 to 25 wt % of total liquid weight calculated as the weight % of the corresponding free acids.